Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11537230 | 0.82 | KMT2A (0.42) | KMT2AMEN1ALDH1A1NLRP3 | |
| SCHEMBL6020342 | 0.78 | ALDH1A1 (0.40) | USP2HSD17B10KMT2AMEN1ALDH1A1 | |
| SCHEMBL6019844 | 0.74 | KDM4E (0.48) | USP2HSD17B10KMT2AMEN1ALDH1A1 | |
| SCHEMBL6021584 | 0.74 | KMT2A (0.51) | USP2HSD17B10POLBKMT2AMEN1 | |
| SCHEMBL11202923 | 0.70 | KMT2A (0.49) | HSD17B10KMT2AMEN1ALDH1A1NLRP3 | |
| SCHEMBL6020760 | 0.69 | EPHX2 (0.51) | USP2HSD17B10KMT2AMEN1ALDH1A1 | |
| SCHEMBL6019550 | 0.69 | ALDH1A1 (0.48) | USP2HSD17B10POLBKMT2AMEN1 | |
| SCHEMBL6020143 | 0.69 | ALDH1A1 (0.49) | USP2HSD17B10POLBALDH1A1HPGD | |
| SCHEMBL6020902 | 0.69 | GAA (0.52) | USP2HSD17B10POLBKMT2AMEN1 | |
| SCHEMBL6020843 | 0.66 | NPC1 (0.42) | POLBKMT2AMEN1ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060252813-A1 | Apparatus for curing a composite laminate | JERINI AG (DE) | 2006-11-09 | — | — | US | claimed |
| EP-1433778-A1 | Use of nitriles as rotamase inhibitors | Jerini AG (DE) | 2004-06-30 | — | — | EP | claimed |
| EP-1433779-A1 | Use of nitriles as inhibitors of non-proteolytic enzymes | Jerini AG (DE) | 2004-06-30 | — | — | EP | claimed |
| US-20060252813-A1 | Apparatus for curing a composite laminate | JERINI AG (DE) | 2006-11-09 | — | — | US | disclosed |
| EP-1433778-A1 | Use of nitriles as rotamase inhibitors | Jerini AG (DE) | 2004-06-30 | — | — | EP | disclosed |
| EP-1433779-A1 | Use of nitriles as inhibitors of non-proteolytic enzymes | Jerini AG (DE) | 2004-06-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252813-A1 | Apparatus for curing a composite laminate | DHX29, HDHD5, DHRS9 | USP2 688/4885HSD17B10 903/4885POLB 3034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.